Median technologies: Full RELIVE results cement eyonis case, to launch in Q4
Yesterday post-market, Median Technologies released the full results from its pivotal RELIVE study, confirming that eyonis LCS, its AI-powered SaMD for lung cancer screening, met all secondary endpoints in addition to the previously announced primary endpoint (p = 0.027). The final data reinforcesMedian Technologies is engaged in medical imaging. Co. develops software applications for the interpretation and management of medical images, whose purpose is to automatically detect and quantitatively measure abnormalities that may be signs of diseases. In addition to being involved in patient care applications, Co.'s software is used today used by biotechnology companies and pharmaceutical companies during their oncology clinical trials. Co.'s activities are structured around three strategic areas: Imaging for patients with cancer; Imaging for oncology clinical trials and Imaging Phenomics.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.